Frontiers in Immunology (Apr 2022)
Elevated α-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control
- Jenifer Masip,
- Jenifer Masip,
- Jenifer Masip,
- Norma Rallón,
- Norma Rallón,
- Elena Yeregui,
- Elena Yeregui,
- Montserrat Olona,
- Montserrat Olona,
- Montserrat Olona,
- Salvador Resino,
- Salvador Resino,
- José M. Benito,
- José M. Benito,
- Consuelo Viladés,
- Consuelo Viladés,
- Consuelo Viladés,
- Consuelo Viladés,
- Graciano García-Pardo,
- Graciano García-Pardo,
- Graciano García-Pardo,
- José Alcamí,
- José Alcamí,
- José Alcamí,
- Ezequiel Ruiz-Mateos,
- Frederic Gómez-Bertomeu,
- Frederic Gómez-Bertomeu,
- Montserrat Vargas,
- Montserrat Vargas,
- Marta Navarro,
- José A. Oteo,
- Juan A. Pineda,
- Anna Martí,
- Anna Martí,
- Anna Martí,
- Verónica Alba,
- Verónica Alba,
- Verónica Alba,
- Francesc Vidal,
- Francesc Vidal,
- Francesc Vidal,
- Francesc Vidal,
- Joaquin Peraire,
- Joaquin Peraire,
- Joaquin Peraire,
- Joaquin Peraire,
- Anna Rull,
- Anna Rull,
- Anna Rull,
- Anna Rull
Affiliations
- Jenifer Masip
- Universitat Rovira i Virgili, Tarragona, Spain
- Jenifer Masip
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Jenifer Masip
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Norma Rallón
- HIV and Viral Hepatitis Research Laboratory, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- Norma Rallón
- Hospital Universitario Rey Juan Carlos, Móstoles, Spain
- Elena Yeregui
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Elena Yeregui
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Montserrat Olona
- Universitat Rovira i Virgili, Tarragona, Spain
- Montserrat Olona
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Montserrat Olona
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Salvador Resino
- Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain
- Salvador Resino
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- José M. Benito
- HIV and Viral Hepatitis Research Laboratory, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- José M. Benito
- Hospital Universitario Rey Juan Carlos, Móstoles, Spain
- Consuelo Viladés
- Universitat Rovira i Virgili, Tarragona, Spain
- Consuelo Viladés
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Consuelo Viladés
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Consuelo Viladés
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Graciano García-Pardo
- Universitat Rovira i Virgili, Tarragona, Spain
- Graciano García-Pardo
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Graciano García-Pardo
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- José Alcamí
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- José Alcamí
- Instituto de Salud Carlos III, AIDS Immunopathology Unit, National Center of Microbiology, Madrid, Spain
- José Alcamí
- HIV Unit, Hospital Clinic-IDIBAPS, Barcelona, Spain
- Ezequiel Ruiz-Mateos
- 0Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, Consejo Superior de Investigaciones Científicas (CSIC), University of Seville, Seville, Spain
- Frederic Gómez-Bertomeu
- Universitat Rovira i Virgili, Tarragona, Spain
- Frederic Gómez-Bertomeu
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Montserrat Vargas
- Universitat Rovira i Virgili, Tarragona, Spain
- Montserrat Vargas
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Marta Navarro
- 1Servicio de Enfermedades Infecciosas, Parc Tauli Hospital Universitari, Sabadell, Spain
- José A. Oteo
- 2Hospital Universitario San Pedro, Centro de Investigación Biomédica de La Rioja (CIBIR), Logroño, Spain
- Juan A. Pineda
- 3Unidad de Investigación Hospital Universitario de Valme, Sevilla, Spain
- Anna Martí
- Universitat Rovira i Virgili, Tarragona, Spain
- Anna Martí
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Anna Martí
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Verónica Alba
- Universitat Rovira i Virgili, Tarragona, Spain
- Verónica Alba
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Verónica Alba
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Francesc Vidal
- Universitat Rovira i Virgili, Tarragona, Spain
- Francesc Vidal
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Francesc Vidal
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Francesc Vidal
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Joaquin Peraire
- Universitat Rovira i Virgili, Tarragona, Spain
- Joaquin Peraire
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Joaquin Peraire
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Joaquin Peraire
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Anna Rull
- Universitat Rovira i Virgili, Tarragona, Spain
- Anna Rull
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Anna Rull
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Anna Rull
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- DOI
- https://doi.org/10.3389/fimmu.2022.822272
- Journal volume & issue
-
Vol. 13
Abstract
Long-term elite controllers (LTECs) are a fascinating small subset of HIV individuals with viral and immunological HIV control in the long term that have been designated as models of an HIV functional cure. However, data on the LTEC phenotype are still scarce, and hence, the metabolomics and lipidomics signatures in the LTEC-extreme phenotype, LTECs with more than 10 years of viral and immunological HIV control, could be pivotal to finding the keys for functional HIV remission. Metabolomics and lipidomics analyses were performed using high-resolution mass spectrometry (ultra-high-performance liquid chromatography–electrospray ionization–quadrupole time of flight [UHPLC-(ESI) qTOF] in plasma samples of 13 patients defined as LTEC-extreme, a group of 20 LTECs that lost viral and/or immunological control during the follow-up study (LTEC-losing) and 9 EC patients with short-term viral and immunological control (less than 5 years; no-LTEC patients). Long-term viral and immunological HIV-1 control was found to be strongly associated with elevated tricarboxylic acid (TCA) cycle function. Interestingly, of the nine metabolites identified in the TCA cycle, α-ketoglutaric acid (p = 0.004), a metabolite implicated in the activation of the mTOR complex, a modulator of HIV latency and regulator of several biological processes, was found to be a key metabolite in the persistent control. On the other hand, a lipidomics panel combining 45 lipid species showed an optimal percentage of separation and an ability to differentiate LTEC-extreme from LTEC-losing, revealing that an elevated lipidomics plasma profile could be a predictive factor for the reignition of viral replication in LTEC individuals.
Keywords